Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Open access
Zhang, Xiu-Li, Cao, Ying, Zheng, Bo · 2023 · BMC Pulmonary Medicine

Published version of a preprint

Abstract

Background: Numerous studies have demonstrated the potential of pirfenidone to enhance the prognosis of patients afflicted with idiopathic pulmonary fibrosis (IPF). Although N-acetylcysteine (NAC) is utilized as an antioxidant in IPF treatment, the combination of NAC and pirfenidone has produced inconsistent outcomes in certain studies. To assess the clinical effectiveness and safety of NAC plus pirfenidone (designated as the treatment group) versus pirfenidone monotherapy (designated as the control group), we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: RCTs of NAC plus pirfenidone were reviewed searching from databases and networks of unpublished and published studies in any language. Using pair-wise meta-analysis, changes in pulmonary function test (PFT) parameters and safety were evaluated. Results: Two independent reviewers selected and obtained data from 5 RCTs ( n = 398), comprising 1 study from Japan, 1 from Europe, and 3 from China. NAS plus pirfenidone as compared to pirfenidone monotherapy for IPF may not reduce the incidence of skin effects(RR 1.26 [95%CI 0.64 to 2.45]) and mortality(RR 0.35 [95%CI 0.07 to 1.68])(both moderate certainty). NAS plus pirfenidone as compared to pirfenidone monotherapy for IPF may not reduce the incidence of at least one side effects(RR 1.00 [95%CI 0.84 to 1.19]; low certainty),severe side effects(RR 0.67 [95%CI 0.30 to 1.47]; low certainty) and gastrointestinal effects(RR 0.67 [95%CI 0.41 to 1.09]; low certainty) with possibly no effect in Δ%DLco(SMD -0.17 [95%CI -0.15 to 0.48]; low certainty). Meanwhile, the effect of NAS plus pirfenidone as compared to pirfenidone monotherapy on ΔFVC(SMD 0.18 [95%CI -0.68 to 1.05]), Δ%FVC(SMD -2.62 [95%CI -5.82 to 0.59]) and Δ6MWT(SMD -0.35 [95%CI -0.98 to 0.28]) is uncertain(extremely low certainty). Conclusion: Moderate certainty evidence suggests that NAS plus pirfenidone, compared to pirfenidone monotherapy for IPF, does not reduce the incidence of skin effects and mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12890-023-02778-w

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of the article evaluation process in this meta-analysis
Fig. 1 Flowchart of the article evaluation process in this meta-analysisCC BY · PubMed Central
Fig. 2 ΔFVC forest plot
Fig. 2 ΔFVC forest plotCC BY · PubMed Central
Fig. 3 Δ%FVC forest plot
Fig. 3 Δ%FVC forest plotCC BY · PubMed Central
Fig. 4 Δ6MWT forest plot
Fig. 4 Δ6MWT forest plotCC BY · PubMed Central
Fig. 5 Δ%DLco forest plot
Fig. 5 Δ%DLco forest plotCC BY · PubMed Central
Fig. 6 Side effects forest plot
Fig. 6 Side effects forest plotCC BY · PubMed Central
Fig. 7 Severe side effects forest plot
Fig. 7 Severe side effects forest plotCC BY · PubMed Central
Fig. 8 Gastrointestinal effects forest plot
Fig. 8 Gastrointestinal effects forest plotCC BY · PubMed Central
Fig. 9 Skin effects forest plot
Fig. 9 Skin effects forest plotCC BY · PubMed Central
Fig. 10 Mortality rates forest plot
Fig. 10 Mortality rates forest plotCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 3

  1. Wen JY, Xie J, Zou LW, et al. Study on curative effects of N-acetylcysteine combined with Pirfenidone in treatment of idiopathic pulmonary interstitial fibrosis. Lab Med Clin. 2019;16(08):1079–81+1085. In Chinese.
  2. Zhou XD, JI GF, Cai TT, et al. Efficacy and mechanism of pirfenidone combined with acetylcysteine in the treatment of patients with IPF. Prog Modern Biomed. 2021;21(06):1064–8. In Chinese.
  3. Zhao HM, Gao F. Efficacy and safety of pirfenidone combined with atomized N-acetylcysteine inhalation in the treatment of idiopathic pulmonary fibrosis. Clin Med. 2023;43(03):113–6. In Chinese.

Cited by

See all 7

Metadata

Authors
Zhang, X.-L., Cao, Y., & Zheng, B.
Corresponding author
Zheng, Bo
Venue
BMC Pulmonary Medicine
Published
2023-11-29
Volume
23
Issue
1
Pages
479-479
ISSN
1471-2466 (ISSN-L)
OpenAlex
W4389145704
Cited by
7
References
39
Citations by year
2026: 2 · 2025: 3 · 2024: 1
FWCI
0.28
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Pulmonary Medicine (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Chengdu Medical College
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, N-acetylcysteine, pirfenidone, combination therapy, lung function, forced vital capacity, diffusing capacity for carbon monoxide, cutaneous adverse events, mortality, drug safety, antioxidant therapy, antifibrotic therapy, treatment efficacy comparison, gastrointestinal adverse effects, drug-drug interactions
MeSH terms
Acetylcysteine, Humans, Pyridones, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12890-023-02778-w
The paper
Zhang, X.-L., Cao, Y., & Zheng, B. (2023). Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-023-02778-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.